Searching for new and effective targets other than EGFR in lung cancer treatment has not been successful until year 2007, when Soda, et al identified the echinoderm microtubule- associated protein-like-4 and the anaplastic lymphoma kinase (EML4-ALK) fusion gene with transforming ability in NSCLC patients [8]. This evidence concerns the gene ALK and non-small cell lung carcinoma.